Literature DB >> 8353648

Wiskott Aldrich syndrome: an immunodeficiency syndrome not rare in Western Australia.

C Somerville1, K D Forsyth.   

Abstract

Wiskott Aldrich syndrome, a combined cellular and humoral X-linked immunodeficiency, is generally considered to be rare. The aim of this study was to ascertain the true prevalence in the paediatric population in Western Australia, describe the clinical features, and summarise the current literature on this unusual condition. All cases of Wiskott Aldrich syndrome presenting to Princess Margaret Hospital in Perth during the period from January 1960 to January 1990 were identified by a retrospective review of case records and by interviewing hospital immunology, haematology and general clinical staff. Nine cases of Wiskott Aldrich syndrome are described, demonstrating that the prevalence of Wiskott Aldrich syndrome in Western Australia is nine times that expected from previous reports. Death occurred in a number of patients before the correct diagnosis was recognised. The clinical features in this group are quite variable. Low isohaemagglutinins, elevated IgE, blunted DTH skin multitest, and very low CD8 numbers are however consistent features. Wiskott Aldrich syndrome may be more prevalent than previously recognised, and should be considered in males with thrombocytopenia and infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353648     DOI: 10.1111/j.1399-3038.1993.tb00069.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  2 in total

Review 1.  Genetics of familial forms of thrombocytopenia.

Authors:  Carlo L Balduini; Anna Savoia
Journal:  Hum Genet       Date:  2012-08-11       Impact factor: 4.132

2.  Clinical and molecular characteristics of 35 Chinese children with Wiskott-Aldrich syndrome.

Authors:  Pamela P W Lee; Tong-Xin Chen; Li-Ping Jiang; Jing Chen; Koon-Wing Chan; Tze-Leung Lee; Marco H K Ho; Shao-Han Nong; Yin Yang; Yong-Jun Fang; Qiang Li; Xiao-Chun Wang; Xi-Qiang Yang; Yu-Lung Lau
Journal:  J Clin Immunol       Date:  2009-03-24       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.